Enfuvirtide: From basic investigations to current clinical use

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 16, 2010, Pages 2701-2713

  Joly, Véronique ^a   Jidar, Kaoutar ^a   Tatay, Mercedes ^a   Yeni, Patrick ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Enfuvirtide; Fusion inhibitor; HIV infection

Indexed keywords

ENFUVIRTIDE; RALTEGRAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG SENSITIVITY; DRUG SUBSTITUTION; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG USE; DRUG WITHDRAWAL; FATIGUE; FEVER; HEADACHE; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE REACTION; INSOMNIA; LYMPHADENOPATHY; MEDLINE; NAUSEA AND VOMITING; NONHUMAN; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PNEUMONIA; REVIEW; VIRUS ENTRY;

ANIMALS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; PEPTIDE FRAGMENTS; SALVAGE THERAPY;

EID: 78049357634     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.522178     Document Type: Review

References (64)

1. De Clercq E. New anti-HIV agents and targets. Med Res Rev 2002;22:531-65
2. Fuzeon [Package insert]. Trimeris Inc. and Roche Laboratories Inc., Durham NC and Nutley NJ; 2003.
3. Kilby JM, Eron J. Novel therapies based on mechanisms ofHIV-1 cell entry. N Engl J Med 2003;348:2228-38
4. Gallaber W, Ball J, Garry J, et al. A general model of the transmembrane proteins of HIV and other retroviruses. AIDS Res Hum Retroviruses 1989;5:431-40
5. Delwart E, Mosialos G, Gilmore T. Retroviral envelope glycoproteins contain a 'leucine zipper'-like repeat. AIDS Res Hum Retroviruses 1989;6:703-6
6. Reeves JD, Gallo SA, Ahmad N, et al. Sensitivity ofHIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density and fusion kinetics. Proc Natl Acad Sci USA 2002;99:16249-54
7. Cooley SA, Lewin SR HIV-1 cell entry and advances in viral entry inhibitor therapy. J Clin Virol 2003;26:121-32
8. Lu M, Blacklow S, Kim P. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995;2:1075-82
9. Carr C, Kim PS. A spring-loaded mechanism for the conformational change on influenza hemaglutinin. Cell 1993;73:823-32
10. Kuhn JH, Radoshitzky SR, Choe H, et al. Severe acute respiratory syndrome coronavirus entry as a target for antiviral therapies. Antivir Ther 2007;12:639-50
11. Dietrich U. HIV-1 entry inhibitors. AIDS Rev 2001;3:89-97
12. Martin-Carbonero L. Discontinuation of the clinical development of the fusion inhibitor T-1249. AIDS Rev 2004;6:61
13. Ketas TJ, Klasse PJ, Spenlehauer C, et al. Entry inhibitors SCH-C, RANTES and T-20 block HIV type I replication in multiple cell types. AIDS Res Hum Retroviruses 2003;19:177-86
14. Derdeyn CA, Decker JM, Sfakianos JN, et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 2000;74:8358-67
15. Melby T, Sista P, DeMasi R, et al. Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res Hum Retroviruses 2006;22:375-85
16. Whitcomb J, Huang W, Fransen S, et al. Analysis of baseline enfuvirtide (T-20) susceptibility and co-receptor tropism in two phase III study populations [abstract 557]. Presented at the 10th Conference on Retrovirus and Opportunistic Infections; 10-14 February 2003; Boston, MA, USA
17. Villahermosa ML, Perez-Alvarez L, Carmona R, et al. Primary resistance mutations to fusion inhibitors and polymorphisms in gp41 sequences of non-B subtypes and recombinants. AIDS 2003;17:1083-6
18. Holguin A, Faudon JL, Labernardiere JL, et al. Susceptibility ofHIV-1 non-B subtypes and recombinant variances to enfuvirtide. J Clin Virol 2007;38:176-80
19. Cilliers T, Patience T, Pillay C, et al. Sensitivity of HIV type 1 subtype C isolates to the entry inhibitor T-20. AIDS Res Hum Retroviruses 2004;20:477-82
20. Center for Drug Evaluation and Research. Application number 21-481. Microbiological review(s). Available from: http://www.fda.gov/cder/foi/nda/2003/ 21481-Fuzeon-Microbr.pdf [Last accessed 31 October 2003]
21. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression ofHIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998;4:1302-7
22. Roman R, Gonzalez D, Lambert C, et al. Uncommon mutations at residue positions critical for enfuvirtide T-20 resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains. J Acquir Immune Defic Syndr 2003;33:134-9
23. Rimsky L, Shugars D, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 1998;72:986-93
24. Poveda E, Rodes B, Lebel-Binay S, et al. Dynamics of enfuvirtide resistance in HIV-infected patients during and after enfuvirtide salvage therapy. J Clin Virol 2005;34:295-301
25. Lalezari JP, Henry K, O'Hearn M, et al.; for the TORO 1 Study Group. Enfuvirtide, an HIV-1 fusion inhibitor, for the drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-85
26. Lazzarin A, Clotet B, Cooper D, et al.; for the TORO 2 study group. Efficacy of enfuvirtide in patients infected with drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2186-95
27. Johnson V, Brun-Vezinet F, Clotet B, et al. Update of drug resistance mutations in HIV-1. Top HIV Med 2008;16:138-45
28. Greenberg ML, Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 2004;54:333-40
29. Labrosse B, Morand-Joubert L, Goubard A, et al. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J Virol 2006;80:8807-19
30. Lu J, Sista P, Giguel F, et al. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol 2004;78:4628-37
31. Menzo S, Casragna A, Monachetti A, et al. Resistance and replicative capacity ofHIV-1 strains selected in vivo by long-term enfuvirtide treatment. New Microbiol 2004;27:51-61
32. Deeks S, Lu J, Hoh R, et al. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. J Infect Dis 2007;195:387-91
33. Su C, Melby R, DeMasi P, et al. Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro. J Clin Virol 2006;36:249-57
34. Xu L, Pozniak A, Wildfire SA, et al. Emergence and evolution of enfuvirtide resistance following long-term therapy involves hepted repeat 2 mutations within gp41. Antimicrob Agents Chemother 2005;49:1113-19
35. Ray N, Blackburn LA, Doms RW. HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide. J Clin Virol 2009;83:2989-95
36. Kilby JM, Lalezari JP, Eron JJ, et al. The safety, plasma pharmacokinetics and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002;18:685-93
37. Bellibas SE, Siddique Z, Dorr A, et al.; for the T20310/NV16056 Study Group. Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy. Pediatr Infect Dis J 2004;23:1137-41
38. Tebas P, Bellos N, Lucasti C, et al. Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function. J Acquir Immune Defic Syndr 2008;47:342-5
39. Raffi F, Battegay M, Rusconi S, et al. Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST. AIDS 2007;21:1977-80
40. Lalezari JP, Eron JJ, Carlson M, et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 2003;17:691-8
41. Lalezari JP, DeJesus E, Northfelt G, et al. A controlled phase II trial evaluating assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir ritonavir and efavirenz in non nucleoside reverse transcriptase inhibitor-naive HIV-infected patients. Antivir Ther 2003;8:279-87
42. Nelson M, Arasteh K, Clotet B, et al. Durable efficacy over 48 weeks in heavily treatment experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005;40:404-12
43. Montaner J, Guimaraes D, Chung J, et al. Prognostic staging of extensively pretreated patients with advanced HIV-1 disease. HIV Clin Trials 2005;6:281-90
44. Reynes J, Arasteh K, Clotet B, et al. TORO: ninety-six week virologic and immunologic response and safety evaluation on enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS 2007;21:533-43
45. Hicks C, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1 infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir RESIST studies: an analysis of combined data from two randomized open-label trials. Lancet 2006;368:466-75
46. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48in treatment-experienced patients with HIV-1 infection in POWER1 and 2: a pooled subgroup analysis of data from two randomized trials. Lancet 2007;369:1169-78
47. Clotet B, Capetti A, Soto-Ramirez LE, et al. A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study. J Antimicrob Chemother 2008;62:1374-8
48. Kaufmann EL, Weber R, Fux CA, et al.; Swiss HIV Cohort Study. Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals. HIV Clin Trials 2009;10:207-14
49. De Castro N, Braun J, Charreau I, et al. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1 infected patients: a randomized open-label trial. Clin Infect Dis 2009;49:1259-67
50. Towner W, Klein D, Kerrigan HL, et al. Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 infected patients well controlled on an enfuvirtide based regimen: 24 weeks results of the CHEER study. J Acquir Immune Defic Syndr 2009;51:367-73
51. Harris M, Larsen G, Montaner JS. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. AIDS 2008;22:1224-6
52. Viard JP, Fagard C, Chaix ML, et al. Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunosuppressed patients. AIDS 2009;23:1383-88
53. Joly V, Fagard C, Descamps D, et al. Intensification of HAART through the addition of enfuvirtide in naive HIV-infected patients with severe immunosuppression does not improve immunological response: results of a prospective randomized multicenter trial (APOLLO-ANRS 130) [abstract 282]. Presented at the 17th Conference on Retrovirus and Opportunistic Infections; 16-19 February 2010; San Francisco, CA, USA
54. Haberl A, Linde R, Reitter A, et al. Use of enfuvirtide in HIV+ pregnant women [abstract 627b]. Presented at the 15th Conference on Retrovirus and Opportunistic Infections; 3-6 February 2008; Boston, MA, USA
55. Teicher E, Abbara C, Duclos-Vallee JC, et al. Enfuvirtide: a safe and effective antiretroviral agent of human immunodeficiency virus-infected patients shortly after liver transplantation. Liver Transplant 2009;15:1336-42
56. Ball RA, Kinchelow T, ISR Substudy Group. Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. J Am Acad Dermatol 2003;49:826-31
57. Maggi P, Ladisa N, Cinori E, et al. Cutaneous injection site reactions to long-term therapy with enfuvirtide. J Antimicrob Chemother 2004;53:678-81
58. Loufty MR, Harris M, Raboud JM, et al. A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector® vs standard needles for enfuvirtide administration. HIV Med 2007;8:427-32
59. Harris M, Joy R, Larsen G, et al. Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector). AIDS 2006;20:719-23
60. Trottier B, Walmsley S, Reynes J, et al. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV 1-infected adults over 48 weeks. J Acquir Immune Defic Syndr 2005;40:413-21
61. Kousignian I, Launay O, Mayaud C, et al. Does enfuvirtide increase the risk of bacterial pneumonia in patients receiving combination antiretroviral therapy? J Antimicrob Chemother 2010;65:138-44
62. Cohen CJ, Clumeck N, Molina JM, et al. Health-related quality of life with enfuvirtide in combination with an optimized background regimen. J Acquir Immune Defic Syndr 2004;37:1140-6
63. Tremblay CL, Kollmann C, Giguel C, et al. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J Acquir Immune Defic Syndr 2000;25:99-102
64. Melby TE, Despirito M, Demasi RA, et al. Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy. AIDS 2007;21:2537-9